Mark J O'Connor Selected Research

olaparib

1/2022	ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
1/2022	PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
1/2021	Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
1/2021	SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
6/2020	Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
4/2020	Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.
1/2020	Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
1/2020	Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
11/2019	AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
4/2019	Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark J O'Connor Research Topics

Disease

49	Neoplasms (Cancer) 01/2022 - 05/2005
16	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2006
8	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 02/2010
7	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2022 - 05/2005
4	Lung Neoplasms (Lung Cancer) 01/2021 - 12/2015
3	Triple Negative Breast Neoplasms 01/2022 - 03/2015
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 10/2011
3	Stomach Neoplasms (Stomach Cancer) 01/2017 - 01/2013
3	Carcinoma (Carcinomatosis) 01/2014 - 11/2008
3	Glioma (Gliomas) 06/2013 - 10/2009
2	Disease Progression 11/2021 - 10/2018
2	Hypoxia (Hypoxemia) 04/2020 - 10/2017
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2019 - 10/2018
2	Hypersensitivity (Allergy) 04/2018 - 05/2010
2	Squamous Cell Carcinoma of Head and Neck 04/2018 - 01/2018
2	Cannabinoid Hyperemesis Syndrome 01/2018 - 09/2017
2	Infections 05/2005 - 08/2004
1	Bites and Stings (Sting) 01/2022
1	Genetic Risk Score 01/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 11/2021
1	Insulin Resistance 11/2021
1	Gout 11/2021
1	Body Weight Changes 01/2021
1	Body Weight (Weight, Body) 01/2021
1	Lewis Lung Carcinoma 01/2020
1	Mucositis 01/2020
1	Genomic Instability 11/2019
1	Hypoglycemia (Reactive Hypoglycemia) 11/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	Circulating Neoplastic Cells 10/2018
1	Melanoma (Melanoma, Malignant) 01/2018
1	Adenocarcinoma of Lung 01/2016
1	Brain Neoplasms (Brain Tumor) 06/2013
1	Neoplasm Metastasis (Metastasis) 01/2013
1	Glioblastoma (Glioblastoma Multiforme) 03/2012
1	Hyperthermia 06/2011
1	Inflammation (Inflammations) 06/2011
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 02/2010

Drug/Important Bio-Agent (IBA)

33	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 06/2008
31	olaparibIBA 01/2022 - 06/2008
15	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2021 - 08/2006
13	Phosphotransferases (Kinase)IBA 01/2022 - 05/2005
12	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2004
8	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2012
8	DNA (Deoxyribonucleic Acid)IBA 04/2019 - 11/2008
6	ceralasertibIBA 01/2022 - 12/2015
5	Pharmaceutical PreparationsIBA 10/2018 - 05/2005
4	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 06/2008
4	Ataxia Telangiectasia Mutated ProteinsIBA 01/2020 - 11/2015
3	PlatinumIBA 01/2022 - 11/2008
3	2- (2,6- dimethylmorpholin- 4- yl)- N- (5- (6- morpholin- 4- yl- 4- oxo- 4H- pyran- 2- yl)- 9H- thioxanthen- 2- yl)acetamideIBA 06/2013 - 10/2009
3	Poly (ADP-Ribose) Polymerase-1IBA 10/2012 - 02/2010
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 02/2011
2	Insulin (Novolin)FDA Link 11/2021 - 10/2009
2	adavosertibIBA 10/2018 - 01/2018
2	Capsaicin (Zostrix)FDA Link 01/2018 - 09/2017
2	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 10/2016 - 01/2013
2	Small Interfering RNA (siRNA)IBA 10/2012 - 05/2010
2	EnzymesIBA 10/2012 - 02/2011
1	Complement System Proteins (Complement)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2022
1	Uric Acid (Urate)IBA 11/2021
1	Allopurinol (Remid)FDA LinkGeneric 11/2021
1	Urethane (Ethyl Carbamate)IBA 01/2021
1	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2021
1	AZD0156IBA 01/2020
1	AZD7648IBA 11/2019
1	Glucose (Dextrose)FDA LinkGeneric 11/2019
1	Glucagon (Glukagon)FDA Link 11/2019
1	Therapeutic UsesIBA 01/2019
1	Biological ProductsIBA 01/2019
1	Estrogen ReceptorsIBA 12/2018
1	AZD3514IBA 12/2018
1	C-terminal binding proteinIBA 12/2018
1	Androgen Receptors (Androgen Receptor)IBA 12/2018
1	A 19IBA 04/2018
1	Mitomycin (Mitomycin-C)FDA LinkGeneric 04/2018
1	SmokeIBA 01/2018
1	NucleotidesIBA 01/2018
1	LigandsIBA 01/2018
1	thiazolyl blueIBA 01/2017
1	human ERBB2 proteinIBA 01/2017
1	AZD2461IBA 10/2016
1	Paclitaxel (Taxol)FDA LinkGeneric 11/2015
1	Vorinostat FDA Link 03/2015
1	Histone Deacetylase InhibitorsIBA 03/2015
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 01/2014
1	CamptothecinIBA 10/2012
1	Temozolomide (Temodar)FDA LinkGeneric 03/2012
1	3-aminobenzamideIBA 10/2011
1	Niacinamide (Nicotinamide)FDA LinkGeneric 10/2011
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 06/2011
1	Caspase 3 (Caspase-3)IBA 02/2011

Therapy/Procedure

17	Therapeutics 11/2021 - 10/2008
10	Drug Therapy (Chemotherapy) 01/2022 - 05/2005
6	Radiotherapy 01/2021 - 10/2011
1	Immunotherapy 01/2018
1	Gastrectomy 01/2013